Clinical trial Recruiting at 1 site Observational Ages 8 to 35

Evaluating pain pathways and nerve regeneration in keratoconus patients after corneal crosslinking

Official title: Neuroplasticity of Pain Pathways and Corneal Afferent Regeneration Following Corneal Crosslinking (CXL) in Keratoconus

Run by Boston Children's Hospital · NCT04439552 · Data updated 2026-11-12

This study is testing how corneal crosslinking affects pain and nerve healing in people with keratoconus to see how their pain changes over time.

Quick facts

Study typeObservational
Ages8 Years to 35 Years
SexAll
Enrollment60 (estimated)
SponsorBoston Children's Hospital
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedOctober 4, 2021
Main results expectedAugust 2027
Study endsDecember 2027
Registry record updatedDecember 19, 2025
Trial IDNCT04439552 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 8-35 with a clinical diagnosis of keratoconus seeking CXL treatment.

Probably not a fit

Patients with significant medical histories, psychiatric disorders, or those who are claustrophobic may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the neuroplasticity of pain pathways and the regeneration of corneal afferent nerves in patients with keratoconus who undergo corneal crosslinking (CXL). Using functional MRI and in vivo corneal microscopy, the study will quantify structural and functional changes associated with acute and chronic pain following CXL. It will also explore the influence of biological and psychological factors on pain outcomes. The central hypothesis is that CXL induces acute pain through trigeminal afferent activation, with chronic pain linked to neuroplastic changes and nerve regeneration.

Why it matters

Potential benefit: If successful, this study could lead to better understanding and management of pain in keratoconus patients post-CXL.

How similar studies have gone: While the approach of using neuroimaging and microscopy in this context is innovative, similar studies have shown promise in understanding pain mechanisms.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

CXL Group

* Age 8-35 years
* Clinical diagnosis of keratoconus and seeking CXL treatment
* English speaking ability sufficient to comprehend consent with parental assistance
* MRI compatible
* Ability to lie still for an MRI session (60 minutes)

Control Group

* Age 8-35 years
* No diagnosis of keratoconus
* English speaking ability sufficient to comprehend consent with parental assistance
* MRI compatible
* Ability to lie still for an MRI session (60 minutes)

Exclusion Criteria (Both Groups):

* Claustrophobic
* Weight \> 285 lbs (weight limit of the MRI table)
* Significant medical history, including:

Current DSM-IV-TR axis I psychiatric disorders. Chronic pain Significant head injury Seizures Brain tumor Cerebrovascular accident Neurological disease aside from migraine HIV-AIDs Prescription medication strongly implicated in causing dry eyes

* Magnetic implants or metal-containing tattoos on their chest or above
* Pregnancy
* History of contact lens wear
* Any allergic response to a numbing eyedrop in the past

Where it's running

  • Boston Children's Hospital
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.